APA (7th ed.) Citation

Yang, L., Chen, T., Zhao, Q., Dong, L., Zhong, W., Liu, W., . . . Xie, R. Is first-line treatment with polatuzumab vedotin–rituximab–cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Yang, Lin, et al. Is First-line Treatment with Polatuzumab Vedotin–rituximab–cyclophosphamide, Doxorubicin and Prednisone (pola-R-CHP) for Previously Untreated Diffuse Large B-cell Lymphoma Cost-effective in China? A Cost-effectiveness Analysis Using a Markov Model. BMJ Publishing Group.

MLA (9th ed.) Citation

Yang, Lin, et al. Is First-line Treatment with Polatuzumab Vedotin–rituximab–cyclophosphamide, Doxorubicin and Prednisone (pola-R-CHP) for Previously Untreated Diffuse Large B-cell Lymphoma Cost-effective in China? A Cost-effectiveness Analysis Using a Markov Model. BMJ Publishing Group.